Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAN-CAR trial of preemptive anti-CMV therapy after major heart surgery
2022-501429-19-00Phase 3Completed
- Sponsor
- Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón
- Start
- Jan 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ganciclovir and valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón. Primary endpoint: Days of good outcome during 30-day follow-up. Started Jan 2023; status: completed.
02
Drugs
ganciclovirvalganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2022-501429-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501429-19-00.